DirectBio
DirectBio offers fast, scalable CRISPR-based diagnostics for pathogen detection. It uses engineered CRISPR enzymes, including AI-designed variants, to achieve high speed and specificity, reducing the need for RNA or DNA extraction and amplification. The product fits the diagnostic assays category for biotech and healthcare settings, targeting laboratories and research organizations. The approach minimizes reagents and steps compared with PCR, enabling easier deployment and broader scalability. The market focus is clinical diagnostics and centralized laboratories seeking rapid, scalable testing.
DirectBio
DirectBio offers fast, scalable CRISPR-based diagnostics for pathogen detection. It uses engineered CRISPR enzymes, including AI-designed variants, to achieve high speed and specificity, reducing the need for RNA or DNA extraction and amplification. The product fits the diagnostic assays category for biotech and healthcare settings, targeting laboratories and research organizations. The approach minimizes reagents and steps compared with PCR, enabling easier deployment and broader scalability. The market focus is clinical diagnostics and centralized laboratories seeking rapid, scalable testing.